On 6/11/19, Amsterdam Molecular Therapeutics (NASDAQ: QURE) stock suffered a major decline of -12.0%, closing at $65.97. Moreover, this decline was accompanied by exceptionally high trading volume at 556% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 2.1% during the last week.
Current PriceTarget Research Rating
QURE is expected to continue to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
Unicure has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Unicure has a very low Appreciation Score of 1 but a very high Power Rating of 89, triggering the Low Neutral Value Trend Rating.
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.